Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: A systematic review with meta-analysis

BJU International

Volumn 111, Issue 6, 2013, Pages 977-983

  Houghton, Baerin B ^a,b   Chalasani, Venu ^a,b,c   Hayne, Dickon ^f   Grimison, Peter ^d   Brown, Christopher S B ^a   Patel, Manish I ^a   Davis, Ian D ^b,e   Stockler, Martin R ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Australian and New Zealand Urogenital and Prostate (ANZUP)   (Australia)

^c Building 52   (Australia)

^d SYDNEY CANCER CENTRE   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

BCG vaccine; epirubicin; intravesical administration; mitomycin C; urinary bladder neoplasm

Indexed keywords

BCG VACCINE; EPIRUBICIN; MITOMYCIN;

ADJUVANT THERAPY; BIBLIOGRAPHIC DATABASE; CANCER RECURRENCE; CYSTITIS; FEVER; HEMATURIA; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 84876892955     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11390.x     Document Type: Review

References (20)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
2. American Cancer Society. Global Cancer Facts & Figures, 2nd edn. Atlanta, GA: Atlanta, USA: American Cancer Society; 2011
3. Schned AR, Andrew AS, Marsit CJ, et al. Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States. Scand J Urol Nephrol 2008; 42: 237-242
4. Holmäng S, Hedelin H, Anderström C, et al. Prospective registration of all patients in a geographical region with newly diagnosed bladder carcinomas during a two-year period. Scand J Urol Nephrol 2000; 34: 95-101
5. Kiemeney LA, Witjes JA, Heijbroek RP, et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150: 60-64
6. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4-34
7. Allard P, Bernard P, Fradet Y, et al. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81: 692-698
8. Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A: 1840-1846
9. Bostwick DG., Natural history of early bladder cancer. J Cell Biochem Suppl 1992; 161: 31-38
10. Morales A, Eidinger D, Bruce AW,. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-183
11. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205-1209
12. Morales A, Ottenhof P, Emerson L,. Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J Urol 1981; 125: 649-651
13. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-314
14. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 43-51
15. Higgins J, Green S,. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2: the Cochrane Collaboration. 2009
16. Ali-El-Dein B, Nabeeh A, Ismail EH, et al. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. J Urol 1999; 162: 339-342
17. Cai T, Nesi G, Tinacci G, et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 2008; 180: 110-115
18. Kaasinen E, Wijkström H, Malmström PU, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol 2003; 43: 637-645
19. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-1129
20. Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174: 1242-1247